Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OmniAb, Inc. filings document the public-company disclosures of an antibody discovery technology business that licenses its platform to pharmaceutical, biotechnology and academic partners. Its Form 8-K reports furnish operating and financial results, partner program updates, guidance-related disclosures and other material events tied to the company’s licensing, service, milestone and royalty model.
The company’s proxy and governance filings cover annual meeting matters, director elections, auditor ratification, shareholder voting results and bylaw amendments addressing proxy-solicitation procedures and stockholder proposal mechanics. OmniAb filings also identify its emerging growth company status, Nasdaq-listed common stock and warrants, and recurring capital-structure and governance disclosure topics.
OmniAb (OABI) reported insider buying by director John L. Higgins. He purchased common stock in two open‑market transactions. On November 6, 2025, he bought 36,223 shares at a weighted average price of $1.41, with trades ranging from $1.38 to $1.45, bringing his beneficial ownership to 2,888,110 shares afterward.
On November 7, 2025, he bought 41,038 shares at a weighted average price of $1.38, with trades ranging from $1.33 to $1.39, increasing his beneficial ownership to 2,929,148 shares after the transaction.
OmniAb, Inc. reported Q3 2025 results showing lower revenue and continued investment in its platform. Total revenue was $2.239 million (vs. $4.172 million a year ago), and net loss was $16.525 million, or $0.14 per share. For the nine months, revenue was $10.290 million and net loss was $50.600 million.
On the balance sheet, cash and cash equivalents were $28.537 million and short‑term investments were $30.963 million as of September 30, 2025. Operating cash used was $30.781 million for the nine months. Shares outstanding were 143,955,400 as of October 28, 2025.
To support operations, OmniAb completed an August 2025 private placement of 21,254,106 shares at $1.40 (or $1.85 for certain insiders) for approximately $30.0 million in gross proceeds; the resale registration became effective on September 19, 2025. The company also recorded a $3.0 million gain from the sale of an ion channel asset in May 2025.
OmniAb, Inc. reported that it issued a press release announcing financial results for the three and nine months ended September 30, 2025. The press release was furnished as Exhibit 99.1 and is not deemed “filed” under the Exchange Act.
The company’s common stock trades as OABI on the Nasdaq Global Market, and its warrants trade as OABIW on the Nasdaq Capital Market.
OmniAb (OABI) disclosed that a director reported the vesting and settlement of 17,769 restricted stock units into common stock on November 1, 2025 (transaction code M).
Following the transaction, the director beneficially owns 93,308 shares directly and holds 20,000 RSUs. The RSU award vests in three substantially equal annual installments beginning November 1, 2023, subject to continued service. The filing was made by one reporting person with direct ownership.
OmniAb (OABI): Form 4 insider transaction
Director Steven Love reported the vesting and settlement of 13,333 Restricted Stock Units into common stock on 11/01/2025 (Code M). Following the transaction, he beneficially owns 71,666 shares directly. Remaining RSUs beneficially owned total 33,334.
Per the footnote, these RSUs vest in three substantially equal annual installments beginning November 1, 2024, subject to continued service. Each RSU represents the right to receive one share of common stock.
OmniAb, Inc. (OABI) filed a Form D reporting a completed private equity offering under Rule 506(b). The filing states a total offering amount of $29,998,991, with $29,998,991 sold and
Schedule 13G/A filed for OmniAb, Inc. (OABI) discloses that several related entities and individuals report beneficial ownership of the issuer's common stock. Ash X LP and RLG GP each report ownership of 8,271,347 shares, representing approximately 5.8% of the outstanding common stock. RLG Capco II LLC holds 1,800,246 shares (about 1.3%) and Joel Greenblatt holds 1,428,571 shares (about 1.0%). Robert Goldstein is reported as beneficial owner of 10,071,593 shares (about 7.0%), reflecting combined holdings through entities he controls. The percentages are calculated using 122,701,294 shares outstanding as of July 30, 2025 plus 21,254,106 additional shares issued on August 25, 2025. The filing states the holdings are not intended to influence control of the issuer.
OmniAb, Inc. (OABI) insider purchase reported by President, CEO and Director Matthew W. Foehr. On 08/26/2025 Mr. Foehr acquired 540,540 shares of common stock in a private placement at $1.85 per share, the closing price on 08/22/2025. After this transaction he beneficially owns 4,341,987 shares in total, which includes 5,211 shares purchased under the company ESPP on 05/30/2025. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on Mr. Foehr's behalf.
OmniAb, Inc. reported the execution of a Securities Purchase Agreement dated August 24, 2025 between the company and the purchasers party thereto and issued a related press release dated August 25, 2025. The filing notes the transaction is subject to customary closing conditions and highlights risks and uncertainties tied to market conditions and satisfaction of those conditions. The company includes a standard forward-looking statements caution and disclaims any obligation to update such statements. The filing is signed by Charles S. Berkman, Chief Legal Officer and Secretary.
Whitefort Capital Management and two co-managing partners report beneficial ownership of 10,240,146 shares of OmniAb, Inc. (OABI), representing 8.4% of the outstanding common stock as of June 30, 2025. The filing states Whitefort Management acts as investment manager for client accounts holding these shares, and Co-Managing Partners David Salanic and Joseph Kaplan may be deemed to beneficially own the same block due to their roles. The 8.4% figure is based on 122,335,336 shares outstanding as of May 1, 2025. The statement affirms the position is not held to change or influence control of the issuer.